Publications
622 results found
Mulla K, Farag S, Moore B, et al., 2023, Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment, Diabetic Medicine, Vol: 40, Pages: 1-10, ISSN: 0742-3071
AimsWe systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoint Inhibitors (ICPI) for cancer, in those with and without diabetes at baseline, and determined the cause of new-onset hyperglycaemia,MethodsRetrospective review of electronic records of those receiving an ICPI for melanoma, lung or renal cancer.ResultsOverall, 959 participants were included. In this study, 103 had diabetes at baseline (10.7%). Those with lung cancer had the highest frequency of diabetes; 131 people had hyperglycaemia (defined as at least one glucose ≥11.1 mmol/L) in the year after starting an ICPI. The incidence was 55% in those with diabetes at baseline, and 8.6% in those without baseline diabetes. Among 74 with new-onset hyperglycaemia (without pre-existing diabetes) 76% was attributable to steroid induced diabetes, with 9.5% due to ICPI Induced diabetes resembling type 1 diabetes.ConclusionsHyperglycaemia is common in persons receiving an ICPI for cancer, including 8.6% of those without known diabetes. While much of this is due to glucocorticoid use, care is needed to avoid missing those with ICPI-induced diabetes who are at risk of diabetic ketoacidosis, which is a medical emergency.
Kroeze SGC, Pavic M, Stellamans K, et al., 2023, Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium., Lancet Oncol, Vol: 24, Pages: e121-e132
Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted therapy or immunotherapy has become a frequently practised and guideline-supported treatment strategy. Despite the increasing use in routine clinical practice, there is little information on the safety of combining SBRT with modern targeted therapy or immunotherapy and a paucity of high-level evidence to guide clinical management. A systematic literature review was performed to identify the toxicity profiles of combined metastases-directed SBRT and targeted therapy or immunotherapy. These results served as the basis for an international Delphi consensus process among 28 interdisciplinary experts who are members of the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) OligoCare consortium. Consensus was sought about risk mitigation strategies of metastases-directed SBRT combined with targeted therapy or immunotherapy; a potential need for and length of interruption to targeted therapy or immunotherapy around SBRT delivery; and potential adaptations of radiation dose and fractionation. Results of this systematic review and consensus process compile the best available evidence for safe combination of metastases-directed SBRT and targeted therapy or immunotherapy for patients with metastatic or oligometastatic cancer and aim to guide today's clinical practice and the design of future clinical trials.
Yang M, Vioix H, Hook ES, et al., 2023, Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping., Value Health
OBJECTIVES: The VISION trial showed durable activity of tepotinib in MET exon 14 (METex14) skipping non-small cell lung cancer. We analyzed health state utilities using patient-reported outcomes from VISION. METHODS: 5-level version of EQ-5D (EQ-5D-5L) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 responses were collected at baseline, every 6 to 12 weeks during treatment, and at the end of treatment and safety follow-up. EQ-5D-5L and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions (QLU-C10D) utilities were derived using United States, Canada, United Kingdom, and Taiwan value sets, where available. Utilities were analyzed with linear mixed models including covariates for progression or time-to-death (TTD). RESULTS: Utilities were derived for 273/291 patients (EQ-5D-5L, 1545 observations; QLU-C10D, 1546 observations). Mean (± SD) US EQ-5D-5L utilities increased after tepotinib initiation, from 0.687 ± 0.287 at baseline to 0.754 ± 0.250 before independently assessed progression, and decreased post progression (0.704 ± 0.288). US QLU-C10D utilities showed similar trends (0.705 ± 0.215, 0.753 ± 0.195, and 0.708 ± 0.209, respectively). Progression-based models demonstrated a statistically significant impact of progression on utilities and predicted higher utilities pre versus post progression. TTD-based models showed statistically significant associations of TTD with utilities and predicted declining utilities as TTD decreased. Prior treatment (yes/no) did not significantly predict utilities in progression- or TTD-based models. Utilities for Canada, United Kingdom, and Taiwan showed comparable trends. CONCLUSIONS: In this first analysis of health state utilities in patients with METex14 skipping non-small cell lung cancer, who received tepotinib, utilities were significantly associated with progression a
Popat S, Ahn M-J, Ekman S, et al., 2023, Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Jan, 10.1007/s11523-022-00941-7, 2023), TARGETED ONCOLOGY, ISSN: 1776-2596
Cerone MA, Mills TC, Sharpe R, et al., 2023, The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care (JAN, 10.1038/s41416-023-02160-x, 2023), BRITISH JOURNAL OF CANCER, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 1
Popat S, Ahn M-J, Ekman S, et al., 2023, Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies, TARGETED ONCOLOGY, ISSN: 1776-2596
Cerone MA, Mills TC, Sharpe R, et al., 2023, The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care, BRITISH JOURNAL OF CANCER, ISSN: 0007-0920
Garcia Campelo MR, Zhou C, Ramalingam SS, et al., 2023, Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort, JOURNAL OF CLINICAL MEDICINE, Vol: 12
Paz-Ares LG, Ciuleanu T-E, Pluzanski A, et al., 2022, Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817, JOURNAL OF THORACIC ONCOLOGY, Vol: 18, Pages: 79-92, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 2
Popat S, Fidyk C, Patel R, 2022, Demographic Analysis of Cancer Patients Who Voluntarily Used a Digital Health Tool to Self-Report Medications, Symptoms and Well-Being, Publisher: ELSEVIER SCIENCE INC, Pages: S396-S396, ISSN: 1098-3015
Ahn MJ, Kim HR, Yang JCH, et al., 2022, Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK plus Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study, CLINICAL LUNG CANCER, Vol: 23, Pages: 720-730, ISSN: 1525-7304
- Author Web Link
- Cite
- Citations: 1
Chouaid C, Girard N, Kron A, et al., 2022, AMIVANTAMAB VERSUS REAL-WORLD CLINICAL PRACTICE IN EUROPE AND THE US FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS, Publisher: ELSEVIER SCIENCE INC, Pages: S32-S32, ISSN: 1098-3015
Stergiopoulos S, King S, Curtis M, et al., 2022, INDIRECT COMPARISON OF EFFICACY AND SAFETY FOR AUMOLERTINIB VS OSIMERTINIB IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC), Publisher: ELSEVIER SCIENCE INC, Pages: S42-S42, ISSN: 1098-3015
Meunier A, Longworth L, Popat S, et al., 2022, DISTRIBUTIONAL COST-EFFECTIVENESS ANALYSIS OF LUNG CANCER TREATMENTS FROM AN NHS ENGLAND PERSPECTIVE, Publisher: ELSEVIER SCIENCE INC, Pages: S339-S339, ISSN: 1098-3015
Kent S, Gupta A, Duffield S, et al., 2022, BIAS ADJUSTING FOR UNMEASURED CONFOUNDERS IN SYNTHETIC CONTROL ANALYSIS (SCA) ESTIMATES OF IMMUNOTHERAPY EFFECTIVENESS IN ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): AN OUTPUT FROM THE Q-BASEL STUDY, Publisher: ELSEVIER SCIENCE INC, Pages: S374-S374, ISSN: 1098-3015
Andres MS, Ramalingam S, Rosen SD, et al., 2022, The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment Including myocarditis and the new entity of non inflammatory left ventricular dysfunction, CARDIO-ONCOLOGY, Vol: 8
Ramagopalan S, Popat S, Gupta A, et al., 2022, Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment, JAMA NETWORK OPEN, Vol: 5, ISSN: 2574-3805
Yang JC-H, Liu G, Lu S, et al., 2022, ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK plus NSCLC, ESMO Asia Congress, Publisher: ELSEVIER, Pages: S1564-S1564, ISSN: 0923-7534
Griesinger F, Popat S, Okhuoya P, et al., 2022, Global real-world (rw) study of patients (pts) with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with first-line (1L) osimertinib: Interim analysis of an rw pt registry in Germany, ESMO Asia Congress, Publisher: ELSEVIER, Pages: S1587-S1587, ISSN: 0923-7534
Fendler A, Shepherd STC, Au L, et al., 2022, Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer, Cell Reports Medicine, Vol: 3, ISSN: 2666-3791
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.
Besse B, Springfeld C, Baik C, et al., 2022, Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naive and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1), EUROPEAN JOURNAL OF CANCER, Vol: 174, Pages: S75-S76, ISSN: 0959-8049
Cho BC, Lin J, Camidge DR, et al., 2022, Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+advanced non-small cell lung cancer (NSCLC), EUROPEAN JOURNAL OF CANCER, Vol: 174, Pages: S1-S2, ISSN: 0959-8049
O'Sullivan H, d'Arienzo PD, Yousaf N, et al., 2022, Response to letter entitled: Re: 'Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla (TM) EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib' Not looking back, EUROPEAN JOURNAL OF CANCER, Vol: 174, Pages: 318-320, ISSN: 0959-8049
Zalcman G, Oulkhouir Y, Cornelissen R, et al., 2022, First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743, Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S1438-S1439, ISSN: 0923-7534
Popat S, Stergiopoulos S, King S, et al., 2022, Indirect treatment comparisons of relative efficacy for aumolertinib vs osimertinib in EGFR-positive non-small cell lung cancer (NSCLC), Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S1012-S1013, ISSN: 0923-7534
Girard N, Popat S, Shoshkova S, et al., 2022, IMreal Cohort 2: Second interim analysis of efficacy and safety data in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) under real-world conditions, Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S1027-S1028, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 1
Zhang YZ, Nicholson AG, Ly F, et al., 2022, Prediction of Clinically Significant Pathological Upstaging in Resected Lung Cancer: Insight from COVID-19 Pandemic (1st wave), Publisher: ELSEVIER SCIENCE INC, Pages: S112-S114, ISSN: 1556-0864
McDonald F, Guckenberger M, Popat S, et al., 2022, HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours, Publisher: ELSEVIER SCIENCE INC, Pages: S492-S492, ISSN: 1556-0864
Zhang YZ, Sherlock S, Brambilla C, et al., 2022, Adenocarcinoma Grade Correlates with PD-L1 and TP53, but not EGFR/KRAS Status and Diagnostic Yield: Analysis of 346 Cases, Publisher: ELSEVIER SCIENCE INC, Pages: S516-S517, ISSN: 1556-0864
O'Sullivan HM, MacMahon S, Cui W, et al., 2022, Frequency and Detectability of Uncommon EGFR Mutations in NSCLC, Publisher: ELSEVIER SCIENCE INC, Pages: S88-S89, ISSN: 1556-0864
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.